<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01517009</url>
  </required_header>
  <id_info>
    <org_study_id>DoCCS</org_study_id>
    <secondary_id>Dutch trialregister</secondary_id>
    <secondary_id>2007-007273-23</secondary_id>
    <nct_id>NCT01517009</nct_id>
  </id_info>
  <brief_title>A Multicenter Phase II Study of Neoadjuvant Docetaxel, Cisplatin and Capecitabine and Protocolized Surgery in Resectable Gastric Cancer</brief_title>
  <acronym>DoCCS</acronym>
  <official_title>A Multicenter Phase II Study of Neoadjuvant Docetaxel, Cisplatin and Capecitabine and Protocolized Surgery in Resectable Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeroen Bosch Ziekenhuis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eindhoven Cancer Registry</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jeroen Bosch Ziekenhuis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the feasibility of chemotherapy, consisting of
      docetaxel, cisplatin and capecitabine given prior to surgery for stomach cancer. Furthermore,
      an extended type of removal of lymph nodes will be implemented.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of patients with (serious) adverse events receiving the combination of 4 courses of docetaxel, cisplatin and capecitabine as neoadjuvant chemotherapy and standardized surgery in resectable localized or locally advanced gastric cancer.</measure>
    <time_frame>18 weeks</time_frame>
    <description>Patients receive every 3 weeks a cycle of chemotherapy, in total 4 cylcles will be given. Surgery will be performed approximately 6 weeks after the last cycle.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of patients receiving a D1-extra-resection as protocolized surgery in resectable gastric cancer</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Gastric Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>60 mg/m2, 1 gift every 3 weeks, in total 4 gifts</description>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>60 mg/m2, one gift every three weeks, in total 4 gift</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>1875 mg/m2 in two equally divided doses day 1-14, repeated every three weeks, in total 4 cycles</description>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>D1extra-resection</intervention_name>
    <description>An extended lymphadenectomy compared to a D1 resection for gastric cancer</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ib-IVa histological proven resectable gastric adenocarcinoma, including
             gastro-oesophageal junction/cardia carcinoma Siewert 2 and 3

          -  ASA 2 or less

          -  Age 18 years or more

          -  No prior radio- or chemotherapy conflicting with the treatment of gastric cancer

          -  Haematology/Renal function/Liver function within designated range

          -  Patient's consent form obtained, signed and dated before beginning specific protocol
             procedures

          -  absence of any psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule; those
             conditions should be discussed with the patient before registration in the trial

          -  before patient registration/randomization, written informed consent must be given
             according to GCP, WMO and local regulations.

        Exclusion Criteria:

          -  Previous or other current malignancies, with the exception of adequately treated in
             situ carcinoma of the cervix uteri or non-melanoma skin cancer

          -  Other current serious illness or medical conditions

          -  Severe cardiac illness (NYHA class III-IV)

          -  Significant neurologic or psychiatric disorders

          -  Uncontrolled infections

          -  Active DIC

          -  Other serious underlying medical conditions that could impair the ability of the
             patient to participate in the study

          -  Known hypersensitivity to docetaxel (or any drug formulated with Polysorbate-80), or
             cisplatin or capecitabine or 5-FU

          -  Definite contraindications for the use of corticosteroids

          -  Use of immunosuppressive or antiviral drugs

          -  Any other experimental drugs within a 4-week period prior to start of neoadjuvant
             chemotherapy and throughout the study period

          -  Pregnant or lactating women

          -  Patients with reproductive potential not implementing adequate contraceptive measures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>VieCuri Hospital</name>
      <address>
        <city>Venlo</city>
        <state>Limburg</state>
        <zip>5912 BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elkerliek Hospital</name>
      <address>
        <city>Helmond</city>
        <state>Noord Brabant</state>
        <zip>5700 AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Hospital</name>
      <address>
        <city>Den Bosch</city>
        <state>Noord-Brabant</state>
        <zip>5200 ME</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Hospital</name>
      <address>
        <city>Eindhoven</city>
        <state>Noord-Brabant</state>
        <zip>5602 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maxima Medical Centre</name>
      <address>
        <city>Veldhoven</city>
        <state>Noord-Brabant</state>
        <zip>5500 MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2011</study_first_submitted>
  <study_first_submitted_qc>January 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2012</study_first_posted>
  <last_update_submitted>June 25, 2013</last_update_submitted>
  <last_update_submitted_qc>June 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jeroen Bosch Ziekenhuis</investigator_affiliation>
    <investigator_full_name>Anneriet Dassen</investigator_full_name>
    <investigator_title>Ms A.E. Dassen, MD, Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Neo-adjuvant chemotherapy</keyword>
  <keyword>D1extra-resection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

